INVO Bioscience (NASDAQ:INVO) Posts Updated Corporate Investor Presentation on Website

On January 7, 2025, NAYA Biosciences Inc., the exact name of the registrant as per its charter, shared an updated corporate investor presentation on its official Investor Relations page available on its corporate website www.nayabiosciences.com. The company made this disclosure in a recent 8-K filing submitted to the SEC.

The added corporate investor presentation, detailed as Exhibit 99.1, features key information that may be pertinent to stakeholders, potential investors, and individuals interested in the company’s latest developments. This presentation is now readily accessible on the aforementioned website.

In addition to the presentation, the company also embedded a Cover Page Interactive Data File (Exhibit 104) within the XBRL document, as part of the financial statements and exhibits under Item 9.01 of the filing.

Steven Shum, the Chief Executive Officer of NAYA Biosciences, officially signed off on the Form 8-K filing on January 7, 2025. This filing fulfills the company’s obligation under the Securities Exchange Act of 1934 and has been duly authorized by the registrant.

This move by NAYA Biosciences Inc. to provide an updated corporate investor presentation reflects the company’s commitment to transparency and effective communication with its investors and the wider financial community.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read INVO Bioscience’s 8K filing here.

About INVO Bioscience

INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.